Please ensure Javascript is enabled for purposes of website accessibility

Why Amedisys Stock Is Crashing Today

By Keith Speights – Aug 5, 2021 at 11:48AM

Key Points

  • Amedisys beat analysts' earnings expectations in Q2, but its revenue came in slightly below the consensus estimate.
  • The main factor weighing on the stock was its lower-than-expected full-year guidance.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company provided disappointing full-year guidance.

What happened

Shares of Amedisys (AMED 0.57%) were down 21.2% as of 11:29 a.m. EDT on Thursday. The big decline came after the home health and hospice company announced its second-quarter results following the market close on Wednesday.

So what

Amedisys reported Q2 revenue of $564.2 million, up 16% year over year. The company posted adjusted earnings of $55.7 million, or $1.69 per share. Analysts' consensus estimate was for adjusted earnings of $1.67 per share. So why did the healthcare stock sink?

A nurse measuring the blood pressure of a seated patient.

Image source: Getty Images.

For one thing, Amedisys' revenue came in a little below analysts' average estimate of $566.2 million. More importantly, though, the company provided disappointing guidance.

Amedisys expects full-year revenue between $2.230 billion and $2.245 billion. Analysts were looking for revenue of $2.32 billion. The company projects adjusted earnings per share in the range of $6.37 to $6.49. That's well below the consensus estimate of $6.96.

COVID-19 is the culprit behind this weaker-than-anticipated guidance. Amedisys stated that the pandemic has negatively impacted its ability to hire and retain staff in its hospice business.

Now what

The big wild card for Amedisys going forward continues to be COVID-19. The company acknowledged that any further disruptions -- including government actions, staff sidelined due to quarantines, and delays in elective procedures -- could make it harder to meet its guidance.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Amedisys Stock Quote
Amedisys
AMED
$91.50 (0.57%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.